Semax is a synthetic heptapeptide derived from adrenocorticotropic hormone (ACTH 4-10) with the addition of a C-terminal Pro-Gly-Pro sequence. It is studied in laboratory and preclinical models for its influence on neuroprotection, cognitive processes, and cellular stress responses. Research has investigated its ability to modulate neurotrophic factor expression, neurotransmitter systems, and oxidative stress pathways.

Ashmarin I.P. et al. (1997).

Semax was developed in Russia in the 1980s–1990s as part of research on synthetic peptides with potential neuromodulatory effects. It was designed to retain the neuroactive core of ACTH while eliminating hormonal activity, thereby providing a stable and non-hormonal peptide for CNS research. Over time, studies expanded into its roles in neuroprotection, synaptic plasticity, and regulation of gene expression in brain models.

Inozemtsev A.N. et al. (2008).

Semax has been studied in neurological, cognitive, and systemic models, with research highlighting its role in neuroprotection, cognitive function, and stress response. Studies also report activity in neurotransmitter modulation, oxidative stress pathways, and recovery processes in preclinical settings.

Key Areas of Research:

• Neurological: neuroprotection, signaling, pathways

• Cognitive: memory, learning, function

• Systemic: stress response, repair, resilience

Together, these findings suggest broad experimental potential for Semax across neurological, cognitive, and systemic pathways. By influencing neurotransmitter systems and supporting protective and restorative responses, Semax provides a versatile platform for research into cognition, stress regulation, and systemic resilience in laboratory models.

Ashmarin I.P. et al., 1995

Ashmarin I.P. et al. (1997). Neuroactive properties of Semax in laboratory and preclinical models. Neurosci Behav Physiol, 27(5): 570–575.

Inozemtsev A.N. et al. (2008). Semax and regulation of gene expression linked to synaptic plasticity and neuronal survival. Bull Exp Biol Med, 146(4): 439–442.

Volodina O.L. et al. (2011). Protective effects of Semax in ischemia-reperfusion injury models. Bull Exp Biol Med, 151(2): 179–183.